HAMSTER CHALLENGE POTENCY ASSAY FOR EVALUATION OF MYCOPLASMA-PNEUMONIAE VACCINES
HAMSTER CHALLENGE POTENCY ASSAY FOR EVALUATION OF MYCOPLASMA-PNEUMONIAE VACCINES
复制标题
DOI：
10.1128/iai.56.9.2450-2457.1988
复制
发表时间：
1988-09-01
影响因子：
3.1
通讯作者：
RAZIN, S
中科院分区：
文献类型：
--
作者：
BARILE, MF;CHANDLER, DKF;RAZIN, S
仓鼠免疫激发试验描述于随附论文（M. F. Barile，D. K. F.钱德勒，H。吉田，M。W.格拉博夫斯基河Harasawa和S.拉辛感染Immun. 56：2443-2449，1988）用于检查通过被动免疫对肺炎支原体疾病的保护作用，并评价福尔马林灭活的全细胞和细胞提取物M.肺炎疫苗。用抗M的超免疫骡抗血清的球蛋白组分进行被动免疫。pneumoniae为仓鼠提供了一些抵抗攻击的保护。当仓鼠主动免疫时，单剂量的福尔马林灭活疫苗仅提供最低限度的保护，而多剂量的该疫苗，特别是与佐剂结合时，提供良好的保护。单剂量的细胞提取物疫苗不能保护动物，但当腹腔内给予引发剂量，然后再腹腔内给予加强剂量时，两次剂量的细胞提取物疫苗可显著减少疾病。代谢抑制抗体水平与M。结果表明，在接种疫苗的仓鼠的血清中检测到肺炎支原体的感染，并且通过肺病理学评分和定殖的减少来测量的保护程度很差，这表明代谢抑制抗体的血清转化率本身不足以测量肺炎支原体的效力。肺炎疫苗。
A hamster immunization challenge assay described in the accompanying paper (M. F. Barile, D. K. F. Chandler, H. Yoshida, M. W. Grabowski, R. Harasawa, and S. Razin, Infect. Immun. 56:2443-2449, 1988) was used to examine protection against Mycoplasma pneumoniae disease by passive immunization and to evaluate the protective potency of a Formalin-inactivated whole-cell and a cell extract M. pneumonia vaccine. Passive immunization with a globulin fraction of hyperimmune mule antiserum to M. pneumoniae provided hamsters some protection against the challenge. When hamsters were actively immunized, a single dose of Formalin-inactivated vaccine provided only minimal protection, whereas multiple doses of this vaccine, particularly when combined with adjuvant, provided good protection. A single dose of the cell extract vaccine did not protect animals, but two doses caused a marked reduction of disease when a priming dose was given intraperitoneally, follwed by a booster dose intratracheally. The correlation between the level of metabolism inhibition antibodies to M. pneumoniae in the sera of vaccinated hamsters and the degree of protection as measured by reduction of lung pathological scores and colonization was poor, indicating that seroconversion rates for metabolism inhibition antibodies are not by themselves adequate to measure the potency of M. pneumoniae vaccines.